Pro Medicus (ASX:PME) share price eyes all-time high

This ASX health imaging company is on the verge of breaking a record.

| More on:
medical imaging doctor amid images of human brains

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price has been one of the best performers on the ASX this year. And today it could be even better as it edges towards a record high.

So far, the health imaging technology company's shares are up almost 70% year-to-date and 120% in the past 12 months.

We take a closer look at what could push Pro Medicus shares to an all-time high this morning.

Pro Medicus share price on the move

Investors remain confident in the Pro Medicus share price as the company continues to impress the market.

During mid-May, Pro Medicus signed an 8-year contract to licence its Visage 7 Enterprise imaging platform to The University of Vermont Health Network Inc. This $14 million deal further cemented the company's growth opportunities across the healthcare market in North America and other regions.

Pro Medicus stated it's won seven contracts in a row, building on its client base and revenue streams.

In addition, the company also recently partnered with healthcare giant Mayo Clinic in a multi-year research agreement announced earlier this month. The framework is aimed at developing and commercialising artificial intelligence, leveraging Pro Medicus' Visage AI Accelerator platform.

The company believes the use of artificial intelligence will play an important role in the healthcare sector in the future. Its latest research collaboration is an integral part of the company's AI strategy in meeting clinical goals with better patient outcomes.

Broker consensus

Over the past week, two brokers rated Pro Medicus shares with similar price points.

The first, Bell Porter, lifted its 12-month price target by 14% to $49.00. The investment firm views Pro Medicus in a positive light but put it on a hold rating due to its current valuation.

Australian investment house Morgans followed suit, raising its price by 20% to $49.69. However, it downgraded its rating from hold to reduce. This could be because the current Pro Medicus share price is almost 20% higher than its recommendation.

Based on valuation metrics, the company commands a market capitalisation of roughly $6 billion, with more than 104 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »